{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:06:21Z","timestamp":1791558381669,"version":"4.3.4"},"reference-count":46,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["1R01AR083552-01A1"],"award-info":[{"award-number":["1R01AR083552-01A1"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009282","name":"United Mitochondrial Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009282","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Chronic Disease"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The impact of Mitochondrial Myopathy (MM) symptoms on functional ability across activities of daily living (ADLs) has not been fully characterized, nor is it understood how MM patients define their key symptoms. Furthermore, it is unclear what MM individuals perceive as a clinically meaningful improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We sought to characterize how MM patients feel about their symptoms in the key MM domains of muscle weakness, muscle fatigue, exercise intolerance, imbalance, and peripheral neuropathy; as well as their functional ability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>We conducted a single-center, observational, qualitative study that involved standardized structured and semi-structured patient interviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Most interview questions were open-ended, allowing individuals to provide personalized narratives that were transcribed in real time. A total of 33 individuals with MM were interviewed either in-person or remotely. Interview transcripts underwent thematic analysis in accordance with grounded theory. Data was presented using a mixed-methods approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Subjects provided extensive narratives that demonstrated the substantial and widespread impact of MM across many aspects of MM patient lives, including the impact of each MM domain of muscle weakness, muscle fatigue, exercise intolerance, imbalance, and peripheral neuropathy on ADLs; the need to adapt to preserve independence and quality of life (QOL); impaired self-perception, participation in social activities, hobbies, and relationships; and change in circumstances over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These meaningful insights highlight the critical and emergent need for approved drug treatment(s) in this profoundly burdened patient population. Our results will serve as a comprehensive resource to inform the physician, patient, industry and advocacy communities on outcome measure selection and clinical trial design; and to help inform regulatory agencies in the United States Food and Drug Administration (FDA) drug approval process for MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406223251344763","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T08:40:32Z","timestamp":1753432832000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["The profound implications of mitochondrial myopathy on activities of daily living: an observational qualitative study of standardized structured and semi-structured patient interviews"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5478-8046","authenticated-orcid":false,"given":"Elizabeth M.","family":"McCormick","sequence":"first","affiliation":[{"name":"Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0480-5709","authenticated-orcid":false,"given":"James T.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9053-141X","authenticated-orcid":false,"given":"Joaquim Diego D.","family":"Santos","sequence":"additional","affiliation":[{"name":"Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Flickinger","sequence":"additional","affiliation":[{"name":"Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"},{"name":"Center for Rehabilitation, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2727-8171","authenticated-orcid":false,"given":"Rui","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA"},{"name":"Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haas","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California\u2014San Diego, San Diego, CA, USA"},{"name":"Department of Pediatrics, University of California\u2014San Diego, San Diego, CA, USA"},{"name":"Division of Neurology, Rady Children\u2019s Hospital, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0743-8879","authenticated-orcid":false,"given":"Zarazuela","family":"Zolkipli-Cunningham","sequence":"additional","affiliation":[{"name":"Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, The Children\u2019s Hospital of Philadelphia, 3500 Civic Center Blvd, Philadelphia, PA 19104, USA"},{"name":"Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24362"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/21501319231193875"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-821751-1.00011-7"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197513"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-821751-1.00014-2"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02411-9"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12546"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0403-5"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2020.09.005"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.012"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01418-9"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2012.12.012"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2009.11.012"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073813481622"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmd2.12316"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265744"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.04.007"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0949-5"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02746-x"},{"key":"e_1_3_4_21_2","first-page":"1126","volume-title":"Neuromuscul Disord","volume":"27","author":"Mancuso M","year":"2017","unstructured":"Mancuso M, McFarland R, Klopstock T, et al. International workshop:: outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16\u201318 November 2016, Rome, Italy. Neuromuscul Disord 2017; 27: 1126\u20131137."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12281"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-821751-1.00002-6"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207402"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12559"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008861"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03421-5"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/crt2.41"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00482-z"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10882-019-09699-9"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.2196\/39172"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0853-y"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-15"},{"key":"e_1_3_4_34_2","volume-title":"Qualitative research for quantitative researchers","author":"Kara H","year":"2022","unstructured":"Kara H. Qualitative research for quantitative researchers. SAGE Publications Ltd, 2022."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/1525822X10388468"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050312118822927"},{"key":"e_1_3_4_38_2","volume-title":"Qualitative inquiry and research design: choosing among five approaches","author":"Creswell J","year":"2024","unstructured":"Creswell J, Poth C. Qualitative inquiry and research design: choosing among five approaches. SAGE Publications, Inc., 2024."},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-040218-044215"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jshs.2023.10.001"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jshs.2023.10.010"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200229"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.902599"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.12317"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.12"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2025.102033"}],"container-title":["Therapeutic Advances in Chronic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223251344763","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406223251344763","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223251344763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:20:11Z","timestamp":1777591211000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406223251344763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":46,"alternative-id":["10.1177\/20406223251344763"],"URL":"https:\/\/doi.org\/10.1177\/20406223251344763","relation":{},"ISSN":["2040-6223","2040-6231"],"issn-type":[{"value":"2040-6223","type":"print"},{"value":"2040-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"article-number":"20406223251344763"}}